Glycine transporter-1 (GlyT-1) in glial cells regulates extracellular levels of glycine, which acts as an obligatory co-agonist at the N-methyl-D-aspartate (NMDA) receptors in the brain. In the present study, we developed a novel radioligand, [ 3
Introduction
Glycine plays an important role in excitatory neurotransmission via strychnine-insensitive glycine sites located on the Nmethyl-D-aspartate (NMDA) receptor [1] [2] [3] [4] . In the central nervous system (CNS), synaptic levels of glycine are regulated by specific sodium/chloride-dependent transporters. The actions of glycine are terminated by reuptake via two high-affinity glycine transporters referred to as glycine transporter 1 (GlyT-1) and glycine transporter 2 (GlyT-2). GlyT-1 and GlyT-2 possess 12 putative transmembrane spanning domains, and share approximately 50% amino acid sequence identity [1] [2] [3] [4] . GlyT-1 is widely expressed in the CNS, where it is present predominantly on glial cells. It is likely that GlyT-1 is responsible for glycine reuptake in forebrain areas, and in some regions it may be co-localized with strychnine-insensitive glycine sites on the NMDA receptor [5] [6] [7] [8] [9] [10] [11] . In contrast to GlyT-1, the distribution of GlyT-2 is predominantly neuronal and much more limited, being mainly restricted to the spinal cord, brainstem and cerebellum [9, 12] . Indeed, GlyT-2 is co-localized with strychnine-sensitive glycine receptors, suggesting that GlyT-2 may be a reliable marker for glycinergic neurons [1] [2] [3] [4] 12, 13] .
Accumulating evidence suggests that a dysfunction in glutamatergic neurotransmission via the NMDA receptors plays a role in the pathophysiology of schizophrenia [14] [15] [16] [17] [18] [19] . Therefore, the potentiation of NMDA receptor function could provide a new approach for the treatment of neuropsychiatric diseases associated with NMDA receptor hypofunction. The effective therapeutic strategy is to increase synaptic levels of glycine by blocking the GlyT-1 in glial cells, because glycine is a co-agonist on the NMDA receptor [20] [21] [22] [23] [24] [25] [26] [27] [28] .
Considering these results together, it would be of great interest to develop radioligands for studying GlyT-1 in the brain. Previously, two sarcosine-based GlyT-1 inhibitors, including [30, 31] , have been reported. However, these two radioligands may be less suitable radioligands for studying GlyT-1 since these radioligands are non-competitive with respect to glycine [32, 33] . Recently, some non-sarcosinebased radioligands such as [ (Figure 1) , is a novel non-sarcosine-based GlyT-1 inhibitor. We found that CHIBA-3007 was a more potent GlyT-1 inhibitor than SSR504734 (this study). In the present study, we report the characterization of a new radioligand [ 3 H]CHIBA-3007 binding to GlyT-1 in the rat brain.
Results

Affinity and specificity of CHIBA-3007 for GlyT-1
The IC 50 values of CHIBA-3007 and SSR504734 for [ 14 C]glycine (10 mM) uptake in the rat brain membrane were 21.468.4 nM (n = 3, mean 6 S.E.M.) and 84.5629.8 nM (n = 3, mean 6 S.E.M.), respectively. Thus, CHIBA-3007 was more potent than SSR504734 for glycine uptake inhibition. Furthermore, CHIBA-3007 (1 mM) was found to be devoid of activity (inhibition lower than 50%) for a 28 standard target binding profile (Table S1 ). The potency of eight GlyT-1 inhibitors (CHIBA-3007, desmethyl-CHIBA-3007, NFPS/ALX5407, LY2365109, Org24598, SSR504734, sarcosine, and glycine) for blocking specific binding of ]CHIBA-3007 binding in the rat brain was similar to the distribution of GlyT-1 in the rat brain reported previously [6, 9, 10, 32] .
Synthesis of [
Discussion
The present study shows that [ [ radioligand for studying the pharmacology and distribution of GlyT-1 in the rat brain in vitro. The major findings of the present study are summarized as follows. First, the potency (IC 50 = 21.4 nM) of CHIBA-3007 for inhibiting [ 14 C]glycine uptake in the rat brain was higher than that (IC 50 = 84.5 nM) of SSR504734, a potent, selective, and orally active GlyT-1 inhibitor [34] . Furthermore, CHIBA-3007 did not show any affinity (less than 50% at 1 mM) for a 28 standard target binding profile (Table S1) , suggesting the high selectivity of CHIBA-3007 for GlyT-1. Second, the kinetic study showed that the specific binding of Previously, we reported that repeated administration of the NMDA receptor antagonist phencyclidine caused an increase of GlyT-1 protein as well as a reduction of extracellular glycine levels in the hippocampus, but not the frontal cortex [35] . The study suggests that increased GlyT-1 protein may play a role in removing the extracellular glycine in the synaptic cleft via GlyT-1, resulting in lower extracellular levels of glycine in the hippocampus [35] . To date, there has been no report about GlyT-1 density in the hippocampus of patients with schizophrenia, although it has been reported that GlyT-1 mRNA and protein levels were not altered in the prefrontal cortex and cerebellum of postmortem brain samples from patients with schizophrenia [36] . Therefore, it would be of interest to study whether levels of GlyT-1 Table 1 and Table 2 The inhibition of [ In conclusion, the present study shows that [ 5 mg) in N,N-dimethylformamide (DMF, 0.3 mL) . The reaction vessel was stirred at 0uC for 30 min. The reaction mixture was applied to a high performance liquid chromatography (HPLC) using an YMC Pack ODS-A column (10 mm in inner diameter 6250 mm in length; YMC Co., Ltd., Kyoto, Japan), comprised of UV absorbance (270 nm). A mixture of CH 3 CN/50 mM CH 3 COONH 4 / CH 3 COOH (350/650/3) was used as the mobile phase at a flow rate of 4 mL/min. The column eluent was collected automatically by using a fraction collector (Model 2110; Bio-Rad Laboratories, K.K., Tokyo, Japan) directly into polypropylene tubes. The 10-mL of each collected fractions were sampled into glass vials with 4 ml of scintillation cocktail (ACS-II; GE Healthcare Japan K.K., Tokyo, Japan). The radioactivity was determined using a liquid scintillation counter (LS-6500; Beckman Coulter, Tokyo, Japan). The radioactive fraction, eluted with a retention time corresponding to that of the authentic standard by was collected into an evaporation flask and evaporated to dryness. The residue was redissolved with 2 ml of ethanol. Chemical and radiochemical purity of [ 3 H]CHIBA-3007 was analyzed by HPLC in a system consisting of a column (YMC-Pack Pro C18, 4.6 mm in inner diameter 6250 mm in length, YMC Co., Ltd., Kyoto, Japan), using CH 3 CN/50 mM CH 3 COONH 4 /CH 3 COOH (350/650/3) as a mobile phase at a flow rate of 1.0 ml/min.
Materials and Methods
Preparation of Rat Brain Membrane
Male Crl: CD (SD) SPF/VF rats (8-10 week olds, 180-200 g)(Japan Charles River Inc., Tokyo, Japan) were used for the experiments. All animal studies were approved by the Animal Care and Use Committee of Chiba University (Permit Number: 22-122). All experiments were performed according to the Guidelines for Animal Experimentation and also conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. All efforts were made to minimize suffering.
After sacrificing the rats by decapitation, the brains were rapidly removed from the skulls. Whole brains or seven specific cerebral regions -the cerebral cortex, striatum, hippocampus, thalamus, midbrain, cerebellum and pons -dissected on ice by the method of Glowinski and Iversen [39] were stored at 280uC until use for the assay.
For the [ 3 H]CHIBA-3007-binding assay, the tissues of whole brains or each specific brain region were homogenized in 15 volumes (w/v) of 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH 7.4 for 30 s on ice. The homogenate was centrifuged at 40,000 g for 15 min at 4uC. The supernatant was discarded and the pellet was re-suspended, homogenized and centrifuged as above. The membrane pellet was washed and resuspended in ice-cold HEPES buffer and was then centrifuged three times. The final pellet was re-suspended in 15 volumes of the buffer (120 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 10 mM HEPES, pH 7.5 at room temperature).
For [ 14 C]glycine uptake, whole brains were homogenized in 10 volumes (w/v) of 0.32 M sucrose, buffered with 10 mM HEPES (pH 7.4). The homogenate was centrifuged at 1,000 g for 10 min to remove nuclei and debris, and then the supernatant was centrifuged again at 20,000 g for 20 min (synaptosomal P 2 fraction). The pellet was washed and re-suspended in ice-cold 0.32 M sucrose, buffered with 10 mM HEPES (pH 7.4) and centrifuged again at 20,000 g for 20 min (washed P 2 fraction). The pellet was re-suspended in 10 volumes of assay buffer with the following composition: 10 mM HEPES buffer (pH 7.4) containing 140 mM NaCl, 5.5 mM KCl, 1.8 mM CaCl 2 , 0.8 mM MgSO 4 , 5 mM glucose and 5 mM L-alanine (HB). The protein concen- ]CHIBA-3007 and the indicated concentrations of test drug in a final volume of 0.5 mL. Non-specific binding was estimated in the presence of 10 mM SSR504734, a potent and selective GlyT-1 inhibitor [34] .
[3H]CHIBA-3007 binding was allowed to occur for 120 min at room temperature for the equilibrium saturation and inhibition studies. The binding reaction was terminated by rapid vacuum filtration onto Whatman GF/B glass filters pretreated with 0.5% polyethyleneimine (SigmaAldrich Co.) using a 24-channel cell harvester (Brandell, Gaithersburg, MD). The filters were washed with 5 mL of icecold assay buffer 3 times, and placed in vials with 4 mL scintillation cocktail. The radioactivity trapped by the filters was determined using a liquid scintillation counter (Beckman LS-6500; Beckman Coulter K.K., Tokyo, Japan).
To examine the pharmacological profiles of [ 3 H]CHIBA-3007 binding, ten compounds were used: desmethyl-CHIBA-3007, CHIBA-3007, CHIBA-3008, SSR504734, NFPS/ALX5407, LY2365109, Org24598, glycine, sarcosine and ALX1393.
Inhibition of [ 14 C]glycine Uptake
The assay of [ 14 C]glycine uptake was started by adding 10 mM 14 C]glycine uptake by eight compoundsdesmethyl-CHIBA-3007, CHIBA-3007, SSR504734, NFPS/ ALX5407, LY2365109, Org24598, sarcosine and glycine-was performed for 15 min at 37uC as reported previously [34] . Nonspecific uptake was estimated in the presence of 30 mM SSR504734. The uptake of [ 14 C]glycine was terminated by rapid vacuum filtration onto Whatman GF/B glass filters pretreated with 0.5% polyethyleneimine. The filters were washed by buffer, and the radioactivity trapped by the filters was determined using a liquid scintillation counter as described above.
Statistical Analysis
The data are shown as the mean 6 standard error of the mean (S.E.M.). The dissociation constant (K d ) and maximal binding (B max ) values from saturation binding and the IC 50 values from binding displacement by each drug were determined using the program GraphPad Prism (GraphPad Software, San Diego, CA). The K i values were calculated from the IC 50 values using the formula of Chung and Prusoff, K i = IC 50 /(1+[L]/K d ) [40] , where the IC 50 was the concentration that resulted in 50% inhibition of specific binding, [L] was the concentration of radioligand used and K d was the dissociation constant. Correlation was analyzed by Pearson's Correlation Coefficient (PASW Statistics 19, Tokyo, Japan). Significance was set at p,0.05. Author Contributions
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